Britt Meelby Jensen
President and Chief Executive Officer (CEO)
Britt has an M.Sc. from Copenhagen Business School, Denmark, and an MBA from Solvay Business School in Brussels, Belgium.
Britt joined Zealand as President and CEO in January 2015. Prior to joining Zealand, she headed the Agilent-owned Danish diagnostics company Dako as the company’s CEO.
Britt has extensive experience from managerial positions in the life science industry, including 11 years’ international experience with Novo Nordisk. Previously, Britt worked for McKinsey & Company and in the EU institutions in Brussels.
Executive Vice President and Chief Financial Officer (CFO)
Mats holds a BA in Business Administration and Economics from the University of Lund, Sweden, and an MBA from IESE University of Navarra, Spain.
Prior to joining Zealand, Mats served as CFO of Swedish Orphan International, a leading European orphan drug Company. Mats has extensive managerial experience and has held CFO positions at Active Biotech and Anoto, both publicly listed on Nasdaq Stockholm. Previously, Mats worked as a management consultant at Gemini Consulting and for Ernst & Young.
Mats is a board member of Auris Medical AG.
Executive Vice President, Chief Medical and Development Officer (CMDO)
Adam is a certified medical doctor and holds a
Doctor of Medical Sciences degree (D.M.Sc./dr.med.) from the University of Copenhagen, Denmark, and an MBA from IMD, Switzerland. Adam has published more than 45 peer-reviewed scientific papers in renowned international journals.
Prior to joining Zealand, Adam led clinical research teams as medical director at Novo Nordisk and worked as a clinician at Rigshospitalet, University of Copenhagen. Adam was a medical and Scientific adviser in the areas of endocrinology, cardiology, gastroenterology and rheumatology.
Adam has significant experience of leading regulatory strategies.
Executive Vice President and Chief Science Officer (CSO)
Andrew holds a Ph.D. from the National Institute for Medical Research in Mill Hill, London, UK. He conducted postdoctoral research at Johns Hopkins School of Medicine, Baltimore, U.S., and also has an MBA from the University of Warwick Business School, UK. Andrew has published more than 25 peer-reviewed scientific papers in renowned international journals.
Prior to joining Zealand, Andrew was general partner and Scientific director of Eclosion2 & Cie SCPC in Switzerland. CEO of Arisgen SA, an Eclosion2 portfolio company developing an oral peptide drug delivery technology.
Andrew has more than 20 years’ experience in international pharmaceutical, biotech and start-up companies, including several years at Shire Pharmaceuticals, Opsona Therapeutics and AstraZeneca.
Senior Vice President, Technical Development and Operations
Ivan holds a Master of Science in Chemical Engineering from the Technical University of Denmark (DTU) and a Master of Business Administration from Harvard Business School.
Prior to joining Zealand, Ivan worked for Novartis in both generics and pharmaceutical manufacturing, as well as in strategy, quality assurance, contract manufacturing and supply chain leadership in Germany, the U.S. and Switzerland.
Ivan was project leader at The Boston Consulting Group in the pharmaceutical R&D and manufacturing areas.
Senior Vice President, Corporate and Business Development
Marino holds a Bachelorís Degree in Business Administration from Concordia University in Montreal, Quebec, and an MBA from the Richard Ivey School of Business at Western University in London, Ontario.
Marino has almost 25 years of global pharma and biotech experience in senior commercial, corporate strategy, and business development roles. He has held various U.S. and international leadership positions of increasing responsibility at pharmaceutical companies, including Synergy Pharma, Aptalis Pharma, Vifor Pharma, Aspreva Pharmaceuticals, Pfizer and Eli Lilly & Co.